Der Gastroenterologe

, Volume 5, Issue 2, pp 156–158


Wichtige neue Erkenntnisse im Überblick

UEGW update

An overview of important new findings


  1. 1.
    Ronkainen J, Aro P, Storskrubb T et al (2009) Natural history of non-erosive reflux disease, the kalixanda study, A population-based study. Gut 58 (Suppl II): OP132Google Scholar
  2. 2.
    Hoffman A, Sar F, Goetz M et al (2009) High definition plus colonoscopy combined with I-scan is superior in the detection and characterization of colorectal neoplasias compared to standard video colonoscopy? A prospective randomized trial. Gut 58 (Suppl II): OP371CrossRefGoogle Scholar
  3. 3.
    Pohl H, Robertson DJ, Farkas DK et al (2009) Erosive and nonerosive reflux disease and risk for Esophageal Adenocarcinoma. Gut 58 (Suppl II): OP139CrossRefGoogle Scholar
  4. 4.
    Kim M, Jung H, Choi K et al (2009) Natural history and management of gastric subpithelial tumors. Gut 58 (Suppl II): P0094CrossRefGoogle Scholar
  5. 5.
    Nowakowska-Dulawa E, Nowak A, Marek T et al (2009) Urgent endoscopic sphincterotomy is beneficial for patients with Acute Biliary Pancreatitis (ABP) without Common Bile Duct Stones (CBDS)? A prospective randomized study. Gut 58 (Suppl II): OP116Google Scholar
  6. 6.
    Sacher-Huvelin S, Le Rhun M, Planche L et al (2009) Wireless capsule colonoscopy versus colonoscopy in patients at average or increased risk for colorectal cancer. Gut 58 (Suppl II): OP005Google Scholar
  7. 7.
    Van Gossum A, Munoz-Navas M, Fernandez-Urien I et al (2009) Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 361: 264–270CrossRefGoogle Scholar
  8. 8.
    Mas-De-Xaxars T, Aldeguer X et al (2009) Searching for representative bacteria in the colonic mucosa of colorectal cancer patients. Gut 58 (Suppl II): OP108Google Scholar
  9. 9.
    Wu S, Rhee KJ, Albesiano E et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15: 1016–1022CrossRefPubMedGoogle Scholar
  10. 10.
    Zeuzem S, Sulkowski M, Lawitz E, McHutchison J et al (2009) Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naïve patients with chronic hepatitis C genotype 1. Oral presentation. 44th Annual Meeting of the European Association for the Study of the LiverGoogle Scholar
  11. 11.
    McHutchison J et al (2009) PROVE3 Final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Hepatology 50: 334A–335AGoogle Scholar
  12. 12.
    Reinisch W, Rubin DT, Bensimon AG et al (2009) Predictors of clinical response and relapse in Crohn’s disease. Gut 58 (Suppl II): OP151Google Scholar
  13. 13.
    Björkesten C af, Nieminen U, Turunen U et al (2009) TNF-alpha antagonists in Crohn’s disease: Results of endoscopy guided therapy. Gut 58 (Suppl II): P1800Google Scholar
  14. 14.
    Colombel J, Rutgeerts P, Reinisch W et al (2009) One year data from the sonic study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Gut 58 (Suppl II): OP323CrossRefGoogle Scholar
  15. 15.
    Maas M, Van Dam RM et al (2009) Wait-and-see policy in clinical complete responders to chemoradiation in rectal cancer: A promising alternative. Gut 58 (Suppl II): P1682Google Scholar

Copyright information

© Springer Medizin Verlag 2010

Authors and Affiliations

  1. 1.I. Medizinische KlinikUniversitätsmedizin MainzMainzDeutschland
  2. 2.Ev. Jung-Stilling-KrankenhausSiegenDeutschland

Personalised recommendations